Objective
Hydrumedical S.A. (HYD) team is composed by a urologist and biomaterials scientists that will revolutionise the treatment of ureteral disorders. Hydrustent is a biodegradable, hydrogel-based, soft, lubricated, and flexible stent. These properties prevent bacterial adhesion (>80% of the stent-related complications) and encrustation development. Nowadays, the application of stents requires a 2nd removal procedure, a burden for patients and healthcare systems. Hydrustent is homogeneously degraded by the urine flow within 7-10 days, eliminating the need of further interventions for its removal. Hydrustent will bring huge health benefits for patients and reduce up to 60% of treatment costs (4.3B€ savings for the health system in EU+US). Validated by the urology community, with a global Ureteral Stents Market raising (~604M€ by 2030), if Hydrustent project is successfully implemented, we intend to reach the EU market in 2024 with profits amounting to 25M€, 5 years after product launch.
Fields of science
Keywords
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended FinanceCoordinator
4805-017 Guimaraes
Portugal
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.